Pancreatic Cancer Research

ResearcherPeking University Third HospitalActive in the last 2 years

Rui Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8838-703X; OpenAlex author ID A5050887292. Sources: OpenAlex.

Their work

Papers
5 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 5

  1. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12943-024-02008-9↗
  2. MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity. Co-author DOI 10.1038/s41419-019-1424-5↗
  3. Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0198938↗
  4. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Co-author DOI 10.1111/dom.12291↗
  5. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. First author DOI 10.1152/ajpendo.00017.2014↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tianpei Hong · 5 shared papers, 2014–2024 · strength 0.48
  2. Wenzhe Si · 2 shared papers, 2019–2024 · strength 0.32
  3. Fei Li · 1 shared paper, 2024 · strength 0.21
  4. Xujun Liu · 1 shared paper, 2019 · strength 0.11
  5. Jingjing Zhang · 1 shared paper, 2018 · strength 0.08
  6. Ran Lu · 1 shared paper, 2018 · strength 0.08
  7. Haiyan Zhao · 1 shared paper, 2014 · strength 0.04
  8. Dianrong Xiu · 1 shared paper, 2014 · strength 0.04
  9. Hejun Zhao · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.